Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $11.90, for a total transaction of $23,800.00. Following the transaction, the president now owns 2,877,138 shares in the company, valued at approximately $34,237,942.20. The trade was a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total transaction of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.

Gyre Therapeutics Price Performance

NASDAQ:GYRE traded up $0.20 during mid-day trading on Friday, reaching $11.98. 29,699 shares of the stock were exchanged, compared to its average volume of 69,938. The business has a fifty day moving average price of $11.20 and a 200 day moving average price of $12.31. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $26.37.

Hedge Funds Weigh In On Gyre Therapeutics

A number of large investors have recently made changes to their positions in GYRE. FMR LLC bought a new stake in shares of Gyre Therapeutics in the third quarter valued at approximately $47,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. State Street Corp raised its holdings in shares of Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company's stock valued at $1,310,000 after buying an additional 8,412 shares during the last quarter. Barclays PLC raised its holdings in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company's stock valued at $116,000 after buying an additional 6,855 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock worth $3,808,000 after purchasing an additional 43,840 shares during the period. Institutional investors and hedge funds own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.